Cholesterol-lowering drug can kill prostate cancer cells

Image
IANS New York
Last Updated : Apr 16 2016 | 11:07 AM IST

A compound initially developed to reduce cholesterol molecule levels can not only halt the progression of prostate cancer but can also kill the deadly cancerous cells in the human body, a new study shows.

The findings suggest that the potential cholesterol drug, when used in combination with commonly used chemotherapeutic drugs, could represent a new therapeutic approach in the fight against prostate cancer, the researchers said.

The compound was found to be effective in reducing human prostate cancer cell growth.

Also, subsequent studies revealed that it caused cancer cell death.

"Often, cancer patients are treated with toxic chemotherapies; however, in our study, we focused on reducing the production of cholesterol in cancer cells, which could kill cancer cells and reduce the need for toxic chemotherapy," said Salman Hyder, professor at University of Missouri in US.

Currently, treatment for primary prostate cancer includes systemic exposure to chemotherapeutic drugs that target androgen receptors located in the cancer cells, which normally bind with hormones such as testosterone.

Although tumour cells may initially respond to these therapies, most eventually develop resistance that causes prostate cancer cells to grow and spread, the researchers noted in the paper published in the journal OncoTargets and Therapy.

Anti-hormone therapies, or chemical castration, also may be used in the fight against prostate cancer.

"Cholesterol also can contribute to the development of anti-hormone resistance because cholesterol is converted into hormones in tumour cells; therefore, these cholesterol-forming pathways are attractive therapeutic targets for the treatment of prostate cancer," Hyder explained.

Using a compound developed for the treatment of high cholesterol called RO 48-8071, the team administered the molecule to human prostate cancer cells.

They then tested the results in mice with human prostate cancer cells. Following injection of the compound, they found that the molecule was effective in reducing tumour growth.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 16 2016 | 10:56 AM IST

Next Story